Royal Bank of Canada
RVPH

Royal Bank of Canada’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Royal Bank of Canada’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
75
– – ﹤0.01% 7613
2025
Q4 		$0 Hold
75
– – ﹤0.01% 7567
2025
Q3 		$1K Hold
75
– – ﹤0.01% 7018
2025
Q2 		$1K Hold
75
– – ﹤0.01% 6926
2025
Q1 		$1K Hold
75
– – ﹤0.01% 6706
2024
Q4 		$3K Buy
+75
New +$2.09K ﹤0.01% 6664
2024
Q3 		– Sell
-12
Closed – – 7359
2024
Q2 		$0 Buy
+12
New +$545 ﹤0.01% 7467
2024
Q1 		– Sell
-2
Closed – – 7515
2023
Q4 		$0 Buy
+2
New +$179 ﹤0.01% 7516
2022
Q4 		– Hold
0
– – – 7642
2022
Q3 		– Hold
0
– – – 7790
2020
Q1 		– Sell
-1,150
Closed -$241K – 6976
2019
Q4 		$241K Buy
1,150
+1
+0.1% +$209 ﹤0.01% 4511
2019
Q3 		$238K Buy
1,149
+683
+147% +$141K ﹤0.01% 4343
2019
Q2 		$96K Buy
466
+21
+5% +$4.27K ﹤0.01% 4900
2019
Q1 		$90K Buy
+445
New +$89.2K ﹤0.01% 4841

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Royal Bank of Canada's RVPH Position: Q1 2026 in Review

Royal Bank of Canada held its REVIVA PHARMA HLDGS INC (RVPH) position steady in Q1 2026 at 75 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7613.

Royal Bank of Canada first reported a position in RVPH in Q1 2019 and has held it in 12 quarters since. The position peaked at $241K in Q4 2019. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Royal Bank of Canada held 75 shares of REVIVA PHARMA HLDGS INC worth $0 as of Q1 2026.
  • Royal Bank of Canada left its REVIVA PHARMA HLDGS INC share count unchanged in Q1 2026.
  • REVIVA PHARMA HLDGS INC made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7613 holding.
  • Royal Bank of Canada first reported a position in REVIVA PHARMA HLDGS INC in Q1 2019 and has held it in 12 quarters since.
  • Royal Bank of Canada's REVIVA PHARMA HLDGS INC position peaked at $241K in Q4 2019.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.